A Phase I/II Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer
ID Number 11-0208
Principal Investigator(s)Randall Holcombe
Department(s) or Division(s)
Hematology and Medical Oncology
Description
The purpose of this study is to investigate if a new Photodynamic (light) Therapy (PDT) is safe and effective in treating colon cancer. PDT involves the use of drug given by mouth called 5-aminolevulenic acid (5-ALA) plus light therapy that will be placed on the tumor. 5-aminolevulenic acid is a substance found normally in your body that comes from your diet. It helps keep your blood cells and muscles healthy. The role of 5-ALA in this study is to make the tumor sensitive to light. Exposing the tumor to light is expected to cause the tumor cells to die and helps your body’s immune system fight against the tumor in the body before it is removed. The doctors believe that this will reduce the chance that the cancer can come back after surgery. 5-ALA based PDT in colon cancer therapy is investigational. This means that both the study drug and the probe being used during PDT have not been approved yet by the Food and Drug Administration (FDA).
You may qualify to take part in this research study because you have been diagnosed with colon cancer and are a candidate for a surgical tumor resection (removal).
Contact Information
(212) 824-7117
(212) 824-7293
Recruiting Patients: Yes